FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008045139> ?p ?o ?g. }

• W2008045139 abstract "Background: The human BET family bromodomains, including BRD2-4 and BRDT proteins, has become a druggable target for the development of specific gene transcription inhibitors. Here, we report the preclinical anti-leukemic activity of OTX015 (OncoEthix SA, Switzerland), a novel pan-BET-BRD inhibitor, as single agent and in combination with different drugs. Material and Methods: Eight established human cell lines from acute and chronic myeloid leukemia (AML, i.e. HL-60 and U-937; CML, i.e. K-562 and NALM-1) and acute lymphoblastic leukemia (ALL, i.e. Jurkat, CCRF-CEM, MOLT-3 and -4) were treated by increasing doses of OTX015. The growth inhibition 50% (GI50) values of OTX015 were evaluated by MTT the assay at 72 h. Protein levels were analyzed by Western blot using commercial antibodies. RNA was extracted using the Qiagen RNAEasy and RT-PCR was performed using Fast SYBR Green on a StepOnePlus Real-Time PCR System. Combination effects were evaluated in HL60, U937, Jurkat and K562 cell lines; OTX015 was administered with daunorubicin, azacytidine, dexamethasone, cytarabine or methotrexate. The 48-h combination index (CI) was determined by median effect plot analysis using CalcuSyn software expressed as the median and range of CI values among cell lines (Chou & Talalay analysis). CI 1: antagonism. Results: Firstly, the anti-proliferative effect of OTX015 was assessed. In HL60, U937 and Jurkat cells, GI50s values were between 230 and 384 nM, while ≥ 1,000 nM for the remaining cell lines. Both OTX015-sensitive and -resistant cells showed similar basal expression levels of BRD2-4, c-MYC, BCL-2, p21 and Cyclin D1 proteins. In sensitive cell lines, OTX015 caused cell cycle arrest in G1 in a time-dependent manner without induction of apoptosis. Likewise, c-MYC mRNA and protein levels were down-regulated after 6-h and up to 72-h treatments with 500 nM OTX015. In Jurkat cells, OTX015 induced up-regulation of BRD2 and 4 mRNA without modifying protein levels. On the other hand, although the OTX015-resistant cell line K562 showed decreased levels of c-MYC mRNA after 4-h and 24-h exposure, protein levels were constant even after 72 h of treatment. Synergy was observed with daunorubicin in OTX015-sensitive and -resistant cell lines (CI=0.8;0.4-0.9). The combination of OTX015 with azacytine or cytarabine was synergistic (CI=0.6;0.6-0.7 and CI=0.8;0.4-0.9, respectively) despite primary resistance of Jurkat and K562 lines to either of the individual drugs. Methotrexate, dexamethasone and panobinostat exerted synergistic effects with OTX015 in 3 out of 4 cell lines (CI=0.5;0.2-0.9; CI=0.3;0.1-0.7 and CI=0.6;0.5-0.7). Conclusion: Our findings indicate that OTX015 enhances in vitro anti-proliferative effects of standard antileukemic agents supporting combination therapy as an important aspect of the clinical development plan. Citation Format: Lucile Astorgues-Xerri, Ramiro Vazquez, Mohamed Bekradda, Esteban Cvitkovic, Patrice Herait, Eric Raymond, Maria E. Riveiro. In vitro evaluation of OTX015, a novel pan-BET-bromodomain (BET-BRD) inhibitor, as single agent and in combination with standard chemotherapy drugs in human leukemic cell lines. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5529. doi:10.1158/1538-7445.AM2014-5529" @default.
• W2008045139 created "2016-06-24" @default.
• W2008045139 creator A5006004932 @default.
• W2008045139 creator A5013952219 @default.
• W2008045139 creator A5042876168 @default.
• W2008045139 creator A5051029234 @default.
• W2008045139 creator A5053091621 @default.
• W2008045139 creator A5055631929 @default.
• W2008045139 creator A5067292546 @default.
• W2008045139 date "2014-09-30" @default.
• W2008045139 modified "2023-10-11" @default.
• W2008045139 title "Abstract 5529: In vitro evaluation of OTX015, a novel pan-BET-bromodomain (BET-BRD) inhibitor, as single agent and in combination with standard chemotherapy drugs in human leukemic cell lines" @default.
• W2008045139 doi "https://doi.org/10.1158/1538-7445.am2014-5529" @default.
• W2008045139 hasPublicationYear "2014" @default.
• W2008045139 type Work @default.
• W2008045139 sameAs 2008045139 @default.
• W2008045139 citedByCount "0" @default.
• W2008045139 crossrefType "proceedings-article" @default.
• W2008045139 hasAuthorship W2008045139A5006004932 @default.
• W2008045139 hasAuthorship W2008045139A5013952219 @default.
• W2008045139 hasAuthorship W2008045139A5042876168 @default.
• W2008045139 hasAuthorship W2008045139A5051029234 @default.
• W2008045139 hasAuthorship W2008045139A5053091621 @default.
• W2008045139 hasAuthorship W2008045139A5055631929 @default.
• W2008045139 hasAuthorship W2008045139A5067292546 @default.
• W2008045139 hasConcept C104317684 @default.
• W2008045139 hasConcept C153911025 @default.
• W2008045139 hasConcept C171122931 @default.
• W2008045139 hasConcept C179464577 @default.
• W2008045139 hasConcept C185592680 @default.
• W2008045139 hasConcept C203014093 @default.
• W2008045139 hasConcept C2776090121 @default.
• W2008045139 hasConcept C2778461978 @default.
• W2008045139 hasConcept C2778903051 @default.
• W2008045139 hasConcept C2780862049 @default.
• W2008045139 hasConcept C41091548 @default.
• W2008045139 hasConcept C502942594 @default.
• W2008045139 hasConcept C55493867 @default.
• W2008045139 hasConcept C74401373 @default.
• W2008045139 hasConcept C86803240 @default.
• W2008045139 hasConcept C8891405 @default.
• W2008045139 hasConcept C98274493 @default.
• W2008045139 hasConceptScore W2008045139C104317684 @default.
• W2008045139 hasConceptScore W2008045139C153911025 @default.
• W2008045139 hasConceptScore W2008045139C171122931 @default.
• W2008045139 hasConceptScore W2008045139C179464577 @default.
• W2008045139 hasConceptScore W2008045139C185592680 @default.
• W2008045139 hasConceptScore W2008045139C203014093 @default.
• W2008045139 hasConceptScore W2008045139C2776090121 @default.
• W2008045139 hasConceptScore W2008045139C2778461978 @default.
• W2008045139 hasConceptScore W2008045139C2778903051 @default.
• W2008045139 hasConceptScore W2008045139C2780862049 @default.
• W2008045139 hasConceptScore W2008045139C41091548 @default.
• W2008045139 hasConceptScore W2008045139C502942594 @default.
• W2008045139 hasConceptScore W2008045139C55493867 @default.
• W2008045139 hasConceptScore W2008045139C74401373 @default.
• W2008045139 hasConceptScore W2008045139C86803240 @default.
• W2008045139 hasConceptScore W2008045139C8891405 @default.
• W2008045139 hasConceptScore W2008045139C98274493 @default.
• W2008045139 hasLocation W20080451391 @default.
• W2008045139 hasOpenAccess W2008045139 @default.
• W2008045139 hasPrimaryLocation W20080451391 @default.
• W2008045139 hasRelatedWork W1567944093 @default.
• W2008045139 hasRelatedWork W1984941008 @default.
• W2008045139 hasRelatedWork W1998805995 @default.
• W2008045139 hasRelatedWork W2014608290 @default.
• W2008045139 hasRelatedWork W2029449207 @default.
• W2008045139 hasRelatedWork W2285789643 @default.
• W2008045139 hasRelatedWork W2343751321 @default.
• W2008045139 hasRelatedWork W2428743865 @default.
• W2008045139 hasRelatedWork W2521450409 @default.
• W2008045139 hasRelatedWork W2553604224 @default.
• W2008045139 hasRelatedWork W2563757607 @default.
• W2008045139 hasRelatedWork W2606328154 @default.
• W2008045139 hasRelatedWork W2735105193 @default.
• W2008045139 hasRelatedWork W2809700647 @default.
• W2008045139 hasRelatedWork W2887567921 @default.
• W2008045139 hasRelatedWork W2917621332 @default.
• W2008045139 hasRelatedWork W2954517278 @default.
• W2008045139 hasRelatedWork W2954732206 @default.
• W2008045139 hasRelatedWork W2979312664 @default.
• W2008045139 hasRelatedWork W3095947069 @default.
• W2008045139 isParatext "false" @default.
• W2008045139 isRetracted "false" @default.
• W2008045139 magId "2008045139" @default.
• W2008045139 workType "article" @default.